Physician profile
Ramy E Hanna
NPI 1366405763
$1,266.42
in general payments reported to CMS, 2019-2025
22 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $91.67 · 2021: $76.07 · 2022: $271 · 2023: $65.95 · 2024: $443 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $249.79 | 2021-2022 | |
| Abbott Laboratories | $179.68 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $116.31 | 2024-2025 | Airsupra, Breztri |
| Alexion Pharmaceuticals, INC. | $91.12 | 2024 | Ultomiris |
| Exact Sciences Corporation | $80.47 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $80.16 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Ardelyx, INC. | $53.81 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $46.35 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $45.56 | 2025 | |
| Glaxosmithkline, LLC. | $44.75 | 2024 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $33.23 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $32.19 | 2025 | Oxlumo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.41 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $26.98 | 2020 | |
| Merck Sharp & Dohme LLC | $24.29 | 2025 | Lagevrio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.33 | 2024 | Arctic Front Advance |
| Corcept Therapeutics | $20.32 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $18.99 | 2025 | Voquezna |
| Amarin Pharma, INC. | $17.50 | 2020 | |
| Currax Pharmaceuticals LLC | $17.38 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.67 | 2020 | |
| Daiichi Sankyo INC. | $16.13 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramy Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.